CagriSema REDEFINE 9 lower doses cut weight by about 21 percent in Phase 3 trial
Two doses below the strength Novo Nordisk filed with the FDA each cut weight by about 21% at 68 weeks against 2% on placebo. The trial was not built to compare the two doses, and CagriSema is still unapproved.
What's new
The Phase 3 REDEFINE 9 trial found that two CagriSema doses below the filed strength cut weight by 20.7% and 21.0% at 68 weeks, against 2.0% on placebo, in 309 adults without diabetes.
Why it matters
It is the first Phase 3 test of lower CagriSema doses, which could widen dosing options if the drug is approved, though the trial was not powered to compare the two doses.
What's next
An FDA decision on the full CagriSema dose is expected in the fourth quarter of 2026. Novo has not said whether it will seek approval for the lower doses.
Two lower doses of CagriSema cut body weight by about 21% over 68 weeks in the Phase 3 CagriSema REDEFINE 9 trial, against 2.0% on placebo. Novo Nordisk released the topline results on 14 November, and the data were shown as a poster at ObesityWeek and published in The Lancet Diabetes & Endocrinology. The weekly injection pairs the amylin analogue cagrilintide with the GLP 1 drug semaglutide. It is not approved in the United States, where an FDA decision on the full dose is expected by the end of 2026.
What the REDEFINE 9 trial tested
REDEFINE 9 enrolled 309 adults without diabetes who had a body mass index of at least 30, or at least 27 with one or more weight related conditions. According to Healio's report of the poster, participants had a mean age of 48 years and a mean BMI of 39.1, and 77% were women. They were randomised in a 2:1:2:1 pattern to one of two CagriSema dose levels, both set below the full dose Novo has filed with the FDA, or to a matching placebo group for each level. All groups also received lifestyle support. The two placebo arms were pooled for the analysis. Each dose was started low and raised in small steps, and the higher level took longer to reach its target than the lower one.
The trial had two coprimary endpoints, both measured at week 68: the percentage change in body weight from baseline and the share of participants who lost at least 5% of their starting weight. Novo Nordisk says REDEFINE 9 is the first Phase 3 study of CagriSema at doses below the full strength tested across the rest of the REDEFINE program. Each dose was compared only with placebo, and the company states that the trial was not powered to find differences between the two dose levels. That design point limits how the results can be read. The study was funded by Novo Nordisk, and the lead author of the journal paper is Sean Wharton of the University of Toronto, according to the company.
CagriSema REDEFINE 9 weight loss results
Under the efficacy estimand, which assumes people stayed on treatment, weight fell by an estimated 20.7% on the higher of the two doses and 21.0% on the lower dose. The pooled placebo group lost 2.0%, the company and the poster report. The estimated differences from placebo were 18.8 and 19.0 percentage points, both with P values below 0.0001. Almost every treated participant crossed the 5% line, with 95.1% on the higher dose and 96.3% on the lower, compared with 33.4% on placebo. Endocrinology Advisor reported that both doses also lowered systolic blood pressure by about 8 to 9 mmHg more than placebo and reduced high sensitivity C reactive protein, a marker of inflammation, along with some blood lipid measures.
Counting everyone who was randomised, the two doses produced average weight loss of 19.4% and 18.6%, against 4.6% on placebo.
The treatment regimen estimand includes everyone who was randomised, also people who stopped the drug or needed rescue treatment. Counting everyone who was randomised, the two doses produced average weight loss of 19.4% and 18.6%, against 4.6% on placebo. Those figures come from Novo Nordisk's results release, and the estimated gaps over placebo narrow to 14.7 and 13.9 percentage points. On this basis 92.8% and 87.7% of the two dose groups reached at least 5% weight loss, against 41.1% on placebo. This estimand sits closer to routine care, where some patients miss doses or stop. The gap between the two sets of numbers reflects lower treated figures and a higher placebo figure once every participant was counted.
| Measure at week 68 | Higher dose | Lower dose | Placebo |
|---|---|---|---|
| Weight loss, efficacy estimand | 20.7% | 21.0% | 2.0% |
| Weight loss, treatment regimen estimand | 19.4% | 18.6% | 4.6% |
| Reached 5% loss, efficacy estimand | 95.1% | 96.3% | 33.4% |
| Any adverse event | 99.0% | 95.1% | 90.2% |
| Stopped for adverse events | 2.9% | 4.9% | 4.9% |
Why the two doses looked alike
Deborah Horn, who directs an obesity medicine center at the University of Texas, presented the poster. Healio reported the average weekly amount each group actually received, and in both groups it sat below the planned target level. Horn said adherence did not explain the similar results. "We know people in general were taking the dose that they were supposed to take," she told Healio. "So that doesn't explain why we have the same efficacy. More for you and I to learn." Because REDEFINE 9 was not powered to compare its two doses, the near identical averages do not show that the lower dose works as well as the higher one. They show only that each beat placebo by a wide margin.
Adverse events were common in every arm, at 99.0% on the higher dose, 95.1% on the lower dose and 90.2% on placebo, according to Endocrinology Advisor's account of the poster. Most were gastrointestinal and mild to moderate. Treatment was stopped because of adverse events by 2.9% of the higher dose group and 4.9% in both the lower dose and placebo groups, and no deaths occurred during the study, Healio reported. The safety profile matched earlier CagriSema trials, the authors concluded. These withdrawal rates are small, and a study of 309 people cannot settle whether a lower dose is easier to tolerate. Horn and several coauthors report consulting or research ties to Novo Nordisk and other obesity drug makers.
What comes next for CagriSema
CagriSema remains investigational in the United States. Novo Nordisk filed a New Drug Application in December 2025 for the full dose for weight management and expects an FDA decision in the fourth quarter of 2026. The company release does not say whether Novo will ask regulators to approve the lower doses tested here. Horn told Healio's ObesityWeek report that she expects approval soon and that lower doses could let doctors and patients choose based on side effects or response. That is her view, not a regulatory finding. At the same meeting the company also showed bone density data from REDEFINE 1, which it calls hypothesis generating.
Comparing CagriSema REDEFINE 9 with other trials needs care. The full dose produced weight reductions of up to 22.7% in earlier REDEFINE studies, Endocrinology Advisor noted, but those trials enrolled different people under different conditions. The first REDEFINE 1 readout in 2024 also fell short of the company's target, which shaped how investors read later data. A head to head result for the lower doses against other obesity drugs does not exist. Until a regulator rules, CagriSema is available only inside registered clinical trials, which are listed on ClinicalTrials.gov under identifiers such as NCT06388187 for this study. Any product sold online under the CagriSema name is unapproved and of unknown content.
Conclusion
The CagriSema REDEFINE 9 trial shows that two doses below the filed strength each cut weight by about a fifth over 68 weeks in adults without diabetes, far more than placebo. The trial was not built to compare those doses, so their similar results answer no question about which one to use. The next fixed point is the FDA decision on the full dose, expected before the end of 2026.